Portal de Periódicos da CAPES

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease

2020; Elsevier BV; Volume: 159; Issue: 4 Linguagem: Inglês

10.1053/j.gastro.2020.05.066

1528-0012

Dana J. Lukin, Anand Kumar, Kaveh Hajifathalian, Reem Z. Sharaiha, Ellen Scherl, Randy Longman, Gabriela Funez-dePagnier, Lucia Duenas-Bianchi, Vinita Jacob, Robert Battat, Tibor I. Krisko, Brett E. Fortune,

COVID-19 Clinical Research Studies

N ew York City is the epicenter of the US coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with local population infection rates estimated at 25%. 1 The impact of COVID-19 on patients with inflammatory bowel disease (IBD) within an epicenter is not well understood.Our study aims were to compare clinical outcomes between COVID-19 patients with and without IBD and to investigate the prevalence and risk factors of COVID-19 in IBD patients. MethodsA matched cohort design was used to compare clinical outcomes in COVID-19 patients with or without IBD.The source cohort of all COVID-19-positive patients at 2 New York hospitals has been described previously 2 (Supplementary Material).The exposure of interest was defined as a pre-existing diagnosis of IBD.Cases (COVID-19 patients with IBD) were matched for decade of age and sex in a 1:2 ratio to unexposed controls (COVID-19 patients without IBD).Outcomes of interest were clinical manifestations of COVID-19, and intensive care unit admission, endotracheal intubation, and death among admitted patients.COVID-19 was defined as confirmed (positive SARS-CoV-2 polymerase chain reaction), or highly suspected (newonset fever >37.8 C and more than 1 new symptom, including cough, sore throat, dyspnea, anosmia, or diarrhea, with a known close contact with COVID-19). 3 separate longitudinal cohort of active IBD patients was used to estimate the prevalence of COVID-19 in IBD patients and evaluate the effects of disease activity and treatment on risk of COVID-19 infection.Exposures of interest were IBD type, clinical, biochemical, and endoscopic indices of disease activity, and IBD treatment.The outcome of interest was diagnosis of COVID-19, as defined above.The details of methods and description of cohorts are available in the Supplementary Material.